Vaccines
Our seasonal influenza vaccine, FluBlok®, has shown excellent performance in the clinic. U.S. approval is expected for the 2009/10 influenza season. Other vaccines in our pipeline focus on pandemic influenza and other viral diseases.
BEVS Technology
Using our patented baculovirus protein expression technology, we produce quality recombinant proteins more quickly, reliably and less expensively than other production systems.
GeneXpress® Services
Our GeneXpress® service business develops and manufactures clinical and research proteins for customers. Currently our 8,000 sq. ft. cGMP facility can produce up to 600L scale.
Research Products
Our line of research products includes many complex viral and human proteins, our serum-free insect cell line expresSF+®, and the BaculoKIT™, our baculovirus protein expression kit.
